ID   NB5R3_HUMAN             Reviewed;         301 AA.
AC   P00387; B1AHF2; B7Z7L3; O75675; Q8TDL8; Q8WTS8; Q9UEN4; Q9UEN5;
AC   Q9UL55; Q9UL56;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 223.
DE   RecName: Full=NADH-cytochrome b5 reductase 3;
DE            Short=B5R;
DE            Short=Cytochrome b5 reductase;
DE            EC=1.6.2.2;
DE   AltName: Full=Diaphorase-1;
DE   Contains:
DE     RecName: Full=NADH-cytochrome b5 reductase 3 membrane-bound form;
DE   Contains:
DE     RecName: Full=NADH-cytochrome b5 reductase 3 soluble form;
GN   Name=CYB5R3; Synonyms=DIA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PRO-66.
RC   TISSUE=Placenta;
RX   PubMed=2479590; DOI=10.1016/0378-1119(89)90299-0;
RA   Tomatsu S., Kobayashi Y., Fukumaki Y., Yubisui T., Orii T., Sakaki Y.;
RT   "The organization and the complete nucleotide sequence of the human
RT   NADH-cytochrome b5 reductase gene.";
RL   Gene 80:353-361(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RA   Voice M.W.;
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Yoon B., Chung H., Ko E., Lee D.;
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT PRO-66, AND VARIANTS
RP   HM GLN-58; PRO-73 AND TYR-204.
RC   TISSUE=Leukocyte;
RA   Lan F.;
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT SER-117.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 8-301 (ISOFORM 1), AND VARIANT PRO-66.
RC   TISSUE=Liver;
RX   PubMed=3035541; DOI=10.1073/pnas.84.11.3609;
RA   Yubisui T., Naitoh Y., Zenno S., Tamura M., Takeshita M., Sakaki Y.;
RT   "Molecular cloning of cDNAs of human liver and placenta NADH-
RT   cytochrome b5 reductase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:3609-3613(1987).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 101-250 (ISOFORM 1).
RA   Diss J.K.J., Fraser S.P., Coombes R.C., Djamgoz M.B.A.;
RT   "Upregulation of voltage-gated Na+ channel expression and metastatic
RT   potential in human breast cancer: correlative studies on cell lines
RT   and biopsy tissues.";
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   PROTEIN SEQUENCE OF 2-25, AND MYRISTOYLATION AT GLY-2.
RX   PubMed=2498303; DOI=10.1093/oxfordjournals.jbchem.a122659;
RA   Murakami K., Yubisui T., Takeshita M., Miyata T.;
RT   "The NH2-terminal structures of human and rat liver microsomal NADH-
RT   cytochrome b5 reductases.";
RL   J. Biochem. 105:312-317(1989).
RN   [14]
RP   PROTEIN SEQUENCE OF 27-301.
RC   TISSUE=Erythrocyte;
RX   PubMed=3700359;
RA   Yubisui T., Miyata T., Iwanaga S., Tamura M., Takeshita M.;
RT   "Complete amino acid sequence of NADH-cytochrome b5 reductase purified
RT   from human erythrocytes.";
RL   J. Biochem. 99:407-422(1986).
RN   [15]
RP   PROTEIN SEQUENCE OF 27-301.
RC   TISSUE=Erythrocyte;
RX   PubMed=6389526;
RA   Yubisui T., Miyata T., Iwanaga S., Tamura M., Yoshida S.,
RA   Takeshita M., Nakajima H.;
RT   "Amino acid sequence of NADH-cytochrome b5 reductase of human
RT   erythrocytes.";
RL   J. Biochem. 96:579-582(1984).
RN   [16]
RP   ALTERNATIVE PROMOTER USAGE.
RX   PubMed=9639531;
RA   Bulbarelli A., Valentini A., De Silvestris M., Cappellini M.D.,
RA   Borgese N.;
RT   "An erythroid-specific transcript generates the soluble form of NADH-
RT   cytochrome b5 reductase in humans.";
RL   Blood 92:310-319(1998).
RN   [17]
RP   MUTAGENESIS OF CYSTEINE RESIDUES.
RX   PubMed=2019583;
RA   Shirabe K., Yubisui T., Nishino T., Takeshita M.;
RT   "Role of cysteine residues in human NADH-cytochrome b5 reductase
RT   studied by site-directed mutagenesis. Cys-273 and Cys-283 are located
RT   close to the NADH-binding site but are not catalytically essential.";
RL   J. Biol. Chem. 266:7531-7536(1991).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-43, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-42, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   MYRISTOYLATION AT GLY-2, CLEAVAGE OF INITIATOR METHIONINE, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=25255805; DOI=10.1038/ncomms5919;
RA   Thinon E., Serwa R.A., Broncel M., Brannigan J.A., Brassat U.,
RA   Wright M.H., Heal W.P., Wilkinson A.J., Mann D.J., Tate E.W.;
RT   "Global profiling of co- and post-translationally N-myristoylated
RT   proteomes in human cells.";
RL   Nat. Commun. 5:4919-4919(2014).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 31-301.
RX   PubMed=15502298; DOI=10.1107/S0907444904020645;
RA   Bando S., Takano T., Yubisui T., Shirabe K., Takeshita M.,
RA   Nakagawa A.;
RT   "Structure of human erythrocyte NADH-cytochrome b5 reductase.";
RL   Acta Crystallogr. D 60:1929-1934(2004).
RN   [25]
RP   VARIANT METHB-CYB5R3 PRO-128.
RX   PubMed=1898726;
RA   Yubisui T., Shirabe K., Takeshita M., Kobayashi Y., Fukumaki Y.,
RA   Sakaki Y., Takano T.;
RT   "Structural role of serine 127 in the NADH-binding site of human NADH-
RT   cytochrome b5 reductase.";
RL   J. Biol. Chem. 266:66-70(1991).
RN   [26]
RP   VARIANTS METHB-CYB5R3 GLN-58 AND PRO-149.
RX   PubMed=1707593;
RA   Katsube T., Sakamoto N., Kobayashi Y., Seki R., Hirano M.,
RA   Tanishima K., Tomoda A., Takazakura E., Yubisui T., Takeshita M.,
RA   Sakaki Y., Fukumaki Y.;
RT   "Exonic point mutations in NADH-cytochrome B5 reductase genes of
RT   homozygotes for hereditary methemoglobinemia, types I and III:
RT   putative mechanisms of tissue-dependent enzyme deficiency.";
RL   Am. J. Hum. Genet. 48:799-808(1991).
RN   [27]
RP   VARIANT METHB-CYB5R3 MET-106.
RX   PubMed=1400360;
RA   Shirabe K., Yubisui T., Borgese N., Tang C.-Y., Hultquist D.E.,
RA   Takeshita M.;
RT   "Enzymatic instability of NADH-cytochrome b5 reductase as a cause of
RT   hereditary methemoglobinemia type I (red cell type).";
RL   J. Biol. Chem. 267:20416-20421(1992).
RN   [28]
RP   VARIANT METHB-CYB5R3 PHE-299 DEL.
RX   PubMed=8119939;
RA   Shirabe K., Fujimoto Y., Yubisui T., Takeshita M.;
RT   "An in-frame deletion of codon 298 of the NADH-cytochrome b5 reductase
RT   gene results in hereditary methemoglobinemia type II (generalized
RT   type). A functional implication for the role of the COOH-terminal
RT   region of the enzyme.";
RL   J. Biol. Chem. 269:5952-5957(1994).
RN   [29]
RP   VARIANTS METHB-CYB5R3 ARG-204 AND MET-273 DEL.
RX   PubMed=7718898;
RA   Vieira L.M., Kaplan J.-C., Kahn A., Leroux A.;
RT   "Four new mutations in the NADH-cytochrome b5 reductase gene from
RT   patients with recessive congenital methemoglobinemia type II.";
RL   Blood 85:2254-2262(1995).
RN   [30]
RP   VARIANT SER-117.
RX   PubMed=9048929; DOI=10.1007/s004390050347;
RA   Jenkins M.M., Prchal J.T.;
RT   "A high-frequency polymorphism of NADH-cytochrome b5 reductase in
RT   African-Americans.";
RL   Hum. Genet. 99:248-250(1997).
RN   [31]
RP   VARIANT METHB-CYB5R3 PRO-73.
RX   PubMed=9695975; DOI=10.1046/j.1365-2141.1998.00782.x;
RA   Wu Y.-S., Huang C.-H., Wan Y., Huang Q.-J., Zhu Z.-Y.;
RT   "Identification of a novel point mutation (Leu72-to-Pro) in the NADH-
RT   cytochrome b5 reductase gene of a patient with hereditary
RT   methaemoglobinaemia type I.";
RL   Br. J. Haematol. 102:575-577(1998).
RN   [32]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 76-83 AND 171-187, AND VARIANT
RP   METHB-CYB5R3 VAL-179.
RX   PubMed=9886302; DOI=10.1046/j.1365-2141.1998.01123.x;
RA   Higasa K., Manabe J.I., Yubisui T., Sumimoto H., Pung-Amritt P.,
RA   Tanphaichitr V.S., Fukumaki Y.;
RT   "Molecular basis of hereditary methaemoglobinaemia, types I and II:
RT   two novel mutations in the NADH-cytochrome b5 reductase gene.";
RL   Br. J. Haematol. 103:922-930(1998).
RN   [33]
RP   VARIANT METHB-CYB5R3 TYR-204.
RX   PubMed=10807796;
RA   Wang Y., Wu Y.-S., Zheng P.-Z., Yang W.-X., Fang G.-A., Tang Y.-C.,
RA   Xie F., Lan F.-H., Zhu Z.-Y.;
RT   "A novel mutation in the NADH-cytochrome b5 reductase gene of a
RT   Chinese patient with recessive congenital methemoglobinemia.";
RL   Blood 95:3250-3255(2000).
RN   [34]
RP   VARIANT METHB-CYB5R3 GLN-58.
RX   PubMed=15622768;
RA   Huang C.-H., Xie Y., Wang Y., Wu Y.-S.;
RT   "Arginine-glutamine replacement at residue 57 of NADH-cytochrome b5
RT   reductase in Chinese hereditary methemoglobinemia.";
RL   Zhonghua Xue Ye Xue Za Zhi 18:200-203(1997).
RN   [35]
RP   VARIANTS METHB-CYB5R3 GLU-256 DEL AND ASP-292.
RX   PubMed=12393396; DOI=10.1182/blood-2002-05-1405;
RA   Percy M.J., Gillespie M.J.S., Savage G., Hughes A.E., McMullin M.F.,
RA   Lappin T.R.J.;
RT   "Familial idiopathic methemoglobinemia revisited: original cases
RT   reveal 2 novel mutations in NADH-cytochrome b5 reductase.";
RL   Blood 100:3447-3449(2002).
RN   [36]
RP   CHARACTERIZATION OF VARIANTS METHB-CYB5R3 GLU-256 DEL AND ASP-292.
RX   PubMed=15953014; DOI=10.1111/j.1365-2141.2005.05526.x;
RA   Percy M.J., Crowley L.J., Davis C.A., McMullin M.F., Savage G.,
RA   Hughes J., McMahon C., Quinn R.J.M., Smith O., Barber M.J.,
RA   Lappin T.R.J.;
RT   "Recessive congenital methaemoglobinaemia: functional characterization
RT   of the novel D239G mutation in the NADH-binding lobe of cytochrome b5
RT   reductase.";
RL   Br. J. Haematol. 129:847-853(2005).
CC   -!- FUNCTION: Desaturation and elongation of fatty acids, cholesterol
CC       biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin
CC       reduction.
CC   -!- CATALYTIC ACTIVITY: NADH + 2 ferricytochrome b5 = NAD(+) + H(+) +
CC       2 ferrocytochrome b5.
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC   -!- SUBUNIT: Component of a complex composed of cytochrome b5, NADH-
CC       cytochrome b5 reductase (CYB5R3) and MOSC2. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Endoplasmic reticulum membrane;
CC       Lipid-anchor; Cytoplasmic side. Mitochondrion outer membrane;
CC       Lipid-anchor; Cytoplasmic side.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Note=Produces the
CC       soluble form found in erythrocytes.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=M;
CC         IsoId=P00387-1; Sequence=Displayed;
CC       Name=2; Synonyms=S;
CC         IsoId=P00387-2; Sequence=VSP_010200;
CC       Name=3;
CC         IsoId=P00387-3; Sequence=VSP_042827;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Isoform 2 is expressed at late stages of
CC       erythroid maturation.
CC   -!- POLYMORPHISM: Ser-117 seems to only be found in persons of African
CC       origin. The allele frequency is 0.23 in African Americans. It was
CC       not found in Caucasians, Asians, Indo-Aryans, or Arabs. There
CC       seems to be no effect on the enzyme activity.
CC       {ECO:0000269|PubMed:9048929}.
CC   -!- DISEASE: Methemoglobinemia CYB5R3-related (METHB-CYB5R3)
CC       [MIM:250800]: A form of methemoglobinemia, a hematologic disease
CC       characterized by the presence of excessive amounts of
CC       methemoglobin in blood cells, resulting in decreased oxygen
CC       carrying capacity of the blood, cyanosis and hypoxia. There are
CC       two types of methemoglobinemia CYB5R3-related. In type 1, the
CC       defect affects the soluble form of the enzyme, is restricted to
CC       red blood cells, and causes well-tolerated methemoglobinemia. In
CC       type 2, the defect affects both the soluble and microsomal forms
CC       of the enzyme and is thus generalized, affecting red cells,
CC       leukocytes and all body tissues. Type 2 methemoglobinemia is
CC       associated with mental deficiency and other neurologic symptoms.
CC       {ECO:0000269|PubMed:10807796, ECO:0000269|PubMed:12393396,
CC       ECO:0000269|PubMed:1400360, ECO:0000269|PubMed:15622768,
CC       ECO:0000269|PubMed:15953014, ECO:0000269|PubMed:1707593,
CC       ECO:0000269|PubMed:1898726, ECO:0000269|PubMed:7718898,
CC       ECO:0000269|PubMed:8119939, ECO:0000269|PubMed:9695975,
CC       ECO:0000269|PubMed:9886302}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the flavoprotein pyridine nucleotide
CC       cytochrome reductase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/dia1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M28713; AAA59900.1; -; Genomic_DNA.
DR   EMBL; M28705; AAA59900.1; JOINED; Genomic_DNA.
DR   EMBL; M28706; AAA59900.1; JOINED; Genomic_DNA.
DR   EMBL; M28707; AAA59900.1; JOINED; Genomic_DNA.
DR   EMBL; M28708; AAA59900.1; JOINED; Genomic_DNA.
DR   EMBL; M28709; AAA59900.1; JOINED; Genomic_DNA.
DR   EMBL; M28710; AAA59900.1; JOINED; Genomic_DNA.
DR   EMBL; M28711; AAA59900.1; JOINED; Genomic_DNA.
DR   EMBL; Y09501; CAA70696.1; -; mRNA.
DR   EMBL; AF361370; AAL87744.1; -; mRNA.
DR   EMBL; AJ010116; CAA09006.1; -; mRNA.
DR   EMBL; AJ010117; CAA09007.1; -; mRNA.
DR   EMBL; AJ010118; CAA09008.1; -; mRNA.
DR   EMBL; AY341030; AAP88936.1; -; Genomic_DNA.
DR   EMBL; BT009821; AAP88823.1; -; mRNA.
DR   EMBL; CR456435; CAG30321.1; -; mRNA.
DR   EMBL; AF061830; AAF06818.1; -; Genomic_DNA.
DR   EMBL; AF061831; AAF06819.1; -; Genomic_DNA.
DR   EMBL; AK302204; BAH13649.1; -; mRNA.
DR   EMBL; Z93241; CAB42843.1; -; Genomic_DNA.
DR   EMBL; Z93241; CAQ08414.1; -; Genomic_DNA.
DR   EMBL; BC004821; AAH04821.1; -; mRNA.
DR   EMBL; AJ310899; CAC84523.1; -; mRNA.
DR   EMBL; AJ310900; CAC84524.1; -; mRNA.
DR   EMBL; M16461; AAA52306.1; -; mRNA.
DR   EMBL; M16462; AAA52307.1; -; mRNA.
DR   CCDS; CCDS14040.1; -. [P00387-2]
DR   CCDS; CCDS33658.1; -. [P00387-1]
DR   CCDS; CCDS54535.1; -. [P00387-3]
DR   PIR; JS0468; RDHUB5.
DR   RefSeq; NP_000389.1; NM_000398.6. [P00387-1]
DR   RefSeq; NP_001123291.1; NM_001129819.2. [P00387-2]
DR   RefSeq; NP_001165131.1; NM_001171660.1. [P00387-3]
DR   RefSeq; NP_001165132.1; NM_001171661.1. [P00387-2]
DR   RefSeq; NP_015565.1; NM_007326.4. [P00387-2]
DR   UniGene; Hs.561064; -.
DR   PDB; 1M91; Model; -; A=1-301.
DR   PDB; 1UMK; X-ray; 1.75 A; A=27-301.
DR   PDBsum; 1M91; -.
DR   PDBsum; 1UMK; -.
DR   ProteinModelPortal; P00387; -.
DR   SMR; P00387; -.
DR   BioGrid; 108071; 44.
DR   DIP; DIP-50463N; -.
DR   IntAct; P00387; 9.
DR   MINT; MINT-5003981; -.
DR   STRING; 9606.ENSP00000354468; -.
DR   ChEMBL; CHEMBL2146; -.
DR   DrugBank; DB03147; Flavin adenine dinucleotide.
DR   DrugBank; DB00157; NADH.
DR   iPTMnet; P00387; -.
DR   PhosphoSitePlus; P00387; -.
DR   SwissPalm; P00387; -.
DR   BioMuta; CYB5R3; -.
DR   DMDM; 127846; -.
DR   REPRODUCTION-2DPAGE; IPI00446235; -.
DR   EPD; P00387; -.
DR   MaxQB; P00387; -.
DR   PaxDb; P00387; -.
DR   PeptideAtlas; P00387; -.
DR   PRIDE; P00387; -.
DR   TopDownProteomics; P00387-1; -. [P00387-1]
DR   TopDownProteomics; P00387-2; -. [P00387-2]
DR   DNASU; 1727; -.
DR   Ensembl; ENST00000352397; ENSP00000338461; ENSG00000100243. [P00387-1]
DR   Ensembl; ENST00000361740; ENSP00000354468; ENSG00000100243. [P00387-3]
DR   Ensembl; ENST00000402438; ENSP00000385679; ENSG00000100243. [P00387-2]
DR   Ensembl; ENST00000407332; ENSP00000384457; ENSG00000100243. [P00387-2]
DR   Ensembl; ENST00000407623; ENSP00000384834; ENSG00000100243. [P00387-2]
DR   GeneID; 1727; -.
DR   KEGG; hsa:1727; -.
DR   UCSC; uc003bcx.4; human. [P00387-1]
DR   CTD; 1727; -.
DR   DisGeNET; 1727; -.
DR   GeneCards; CYB5R3; -.
DR   HGNC; HGNC:2873; CYB5R3.
DR   HPA; HPA001566; -.
DR   MalaCards; CYB5R3; -.
DR   MIM; 250800; phenotype.
DR   MIM; 613213; gene.
DR   neXtProt; NX_P00387; -.
DR   OpenTargets; ENSG00000100243; -.
DR   Orphanet; 139373; Recessive hereditary methemoglobinemia type 1.
DR   Orphanet; 139380; Recessive hereditary methemoglobinemia type 2.
DR   PharmGKB; PA27331; -.
DR   eggNOG; KOG0534; Eukaryota.
DR   eggNOG; COG0543; LUCA.
DR   GeneTree; ENSGT00390000008881; -.
DR   HOGENOM; HOG000175005; -.
DR   HOVERGEN; HBG052580; -.
DR   InParanoid; P00387; -.
DR   KO; K00326; -.
DR   OMA; PVWFLYN; -.
DR   OrthoDB; EOG091G0EIS; -.
DR   PhylomeDB; P00387; -.
DR   TreeFam; TF314333; -.
DR   BioCyc; MetaCyc:HS02015-MONOMER; -.
DR   BRENDA; 1.6.2.2; 2681.
DR   Reactome; R-HSA-196836; Vitamin C (ascorbate) metabolism.
DR   Reactome; R-HSA-211945; Phase 1 - Functionalization of compounds.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SABIO-RK; P00387; -.
DR   EvolutionaryTrace; P00387; -.
DR   GeneWiki; CYB5R3; -.
DR   GenomeRNAi; 1727; -.
DR   PRO; PR:P00387; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000100243; -.
DR   CleanEx; HS_CYB5R3; -.
DR   ExpressionAtlas; P00387; baseline and differential.
DR   Genevisible; P00387; HS.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005833; C:hemoglobin complex; TAS:ProtInc.
DR   GO; GO:0005811; C:lipid particle; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:Ensembl.
DR   GO; GO:0005741; C:mitochondrial outer membrane; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0043531; F:ADP binding; IEA:Ensembl.
DR   GO; GO:0016208; F:AMP binding; IEA:Ensembl.
DR   GO; GO:0004128; F:cytochrome-b5 reductase activity, acting on NAD(P)H; TAS:Reactome.
DR   GO; GO:0071949; F:FAD binding; IDA:UniProtKB.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IEA:Ensembl.
DR   GO; GO:0051287; F:NAD binding; IEA:Ensembl.
DR   GO; GO:0016491; F:oxidoreductase activity; IBA:GO_Central.
DR   GO; GO:0008015; P:blood circulation; TAS:ProtInc.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0019852; P:L-ascorbic acid metabolic process; TAS:Reactome.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:Reactome.
DR   InterPro; IPR017927; Fd_Rdtase_FAD-bd.
DR   InterPro; IPR001709; Flavoprot_Pyr_Nucl_cyt_Rdtase.
DR   InterPro; IPR001834; NADH-Cyt_B5_reductase.
DR   InterPro; IPR008333; OxRdtase_FAD-bd_dom.
DR   InterPro; IPR001433; OxRdtase_FAD/NAD-bd.
DR   InterPro; IPR017938; Riboflavin_synthase-like_b-brl.
DR   Pfam; PF00970; FAD_binding_6; 1.
DR   Pfam; PF00175; NAD_binding_1; 1.
DR   PRINTS; PR00406; CYTB5RDTASE.
DR   PRINTS; PR00371; FPNCR.
DR   SUPFAM; SSF63380; SSF63380; 1.
DR   PROSITE; PS51384; FAD_FR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative promoter usage;
KW   Alternative splicing; Cholesterol biosynthesis;
KW   Cholesterol metabolism; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Endoplasmic reticulum;
KW   FAD; Flavoprotein; Lipid biosynthesis; Lipid metabolism; Lipoprotein;
KW   Membrane; Mitochondrion; Mitochondrion outer membrane; Myristate; NAD;
KW   Oxidoreductase; Phosphoprotein; Polymorphism; Reference proteome;
KW   Steroid biosynthesis; Steroid metabolism; Sterol biosynthesis;
KW   Sterol metabolism.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:25255805}.
FT   CHAIN         2    301       NADH-cytochrome b5 reductase 3 membrane-
FT                                bound form.
FT                                /FTId=PRO_0000019392.
FT   CHAIN        27    301       NADH-cytochrome b5 reductase 3 soluble
FT                                form.
FT                                /FTId=PRO_0000019394.
FT   DOMAIN       40    152       FAD-binding FR-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00716}.
FT   NP_BIND     132    147       FAD. {ECO:0000250}.
FT   NP_BIND     171    206       FAD. {ECO:0000250}.
FT   MOD_RES      42     42       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      43     43       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     120    120       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9DCN2}.
FT   LIPID         2      2       N-myristoyl glycine.
FT                                {ECO:0000269|PubMed:2498303,
FT                                ECO:0000269|PubMed:25255805}.
FT   VAR_SEQ       1     23       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_010200.
FT   VAR_SEQ       1      7       MGAQLST -> MNRSLLVGCMQSKDIWGREESICERLKQDG
FT                                LDVERAESWE (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042827.
FT   VARIANT      58     58       R -> Q (in METHB-CYB5R3; type 1; 62% of
FT                                activity; dbSNP:rs121965007).
FT                                {ECO:0000269|PubMed:15622768,
FT                                ECO:0000269|PubMed:1707593,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_004619.
FT   VARIANT      66     66       S -> P (in dbSNP:rs1130706).
FT                                {ECO:0000269|PubMed:2479590,
FT                                ECO:0000269|PubMed:3035541,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018419.
FT   VARIANT      73     73       L -> P (in METHB-CYB5R3; type 1;
FT                                dbSNP:rs121965013).
FT                                {ECO:0000269|PubMed:9695975,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_010750.
FT   VARIANT     106    106       V -> M (in METHB-CYB5R3; type 1; 77% of
FT                                activity; dbSNP:rs121965009).
FT                                {ECO:0000269|PubMed:1400360}.
FT                                /FTId=VAR_004620.
FT   VARIANT     117    117       T -> S (in dbSNP:rs1800457).
FT                                {ECO:0000269|PubMed:9048929,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_010751.
FT   VARIANT     128    128       S -> P (in METHB-CYB5R3; type 2;
FT                                Hiroshima; dbSNP:rs121965006).
FT                                {ECO:0000269|PubMed:1898726}.
FT                                /FTId=VAR_004621.
FT   VARIANT     149    149       L -> P (in METHB-CYB5R3;
FT                                dbSNP:rs121965008).
FT                                {ECO:0000269|PubMed:1707593}.
FT                                /FTId=VAR_004622.
FT   VARIANT     179    179       A -> V (in METHB-CYB5R3; type 1;
FT                                dbSNP:rs201232518).
FT                                {ECO:0000269|PubMed:9886302}.
FT                                /FTId=VAR_010752.
FT   VARIANT     204    204       C -> R (in METHB-CYB5R3; type 2;
FT                                dbSNP:rs121965011).
FT                                {ECO:0000269|PubMed:7718898}.
FT                                /FTId=VAR_010753.
FT   VARIANT     204    204       C -> Y (in METHB-CYB5R3; type 1;
FT                                dbSNP:rs121965015).
FT                                {ECO:0000269|PubMed:10807796,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_010754.
FT   VARIANT     256    256       Missing (in METHB-CYB5R3; type 1; retains
FT                                approximately 38% of residual diaphorase
FT                                activity). {ECO:0000269|PubMed:12393396,
FT                                ECO:0000269|PubMed:15953014}.
FT                                /FTId=VAR_037315.
FT   VARIANT     273    273       Missing (in METHB-CYB5R3; type 2).
FT                                {ECO:0000269|PubMed:7718898}.
FT                                /FTId=VAR_010755.
FT   VARIANT     292    292       G -> D (in METHB-CYB5R3; type 1; retains
FT                                approximately 58% of residual diaphorase
FT                                activity; dbSNP:rs121965016).
FT                                {ECO:0000269|PubMed:12393396,
FT                                ECO:0000269|PubMed:15953014}.
FT                                /FTId=VAR_037316.
FT   VARIANT     299    299       Missing (in METHB-CYB5R3; type2; almost
FT                                complete loss of activity).
FT                                {ECO:0000269|PubMed:8119939}.
FT                                /FTId=VAR_004623.
FT   CONFLICT     28     32       QRSTP -> RWPRA (in Ref. 11; AAA52307).
FT                                {ECO:0000305}.
FT   CONFLICT     29     29       R -> G (in Ref. 1; AAA59900).
FT                                {ECO:0000305}.
FT   CONFLICT     31     31       T -> K (in Ref. 4; CAA09006/CAA09007/
FT                                CAA09008). {ECO:0000305}.
FT   CONFLICT     34     35       IT -> LA (in Ref. 11; AAA52307).
FT                                {ECO:0000305}.
FT   CONFLICT    187    188       ML -> IV (in Ref. 4; CAA09006/CAA09007).
FT                                {ECO:0000305}.
FT   CONFLICT    191    192       IR -> MS (in Ref. 4; CAA09006/CAA09007).
FT                                {ECO:0000305}.
FT   CONFLICT    192    192       R -> G (in Ref. 11; AAA52306).
FT                                {ECO:0000305}.
FT   CONFLICT    233    234       FK -> CN (in Ref. 4; CAA09006/CAA09007).
FT                                {ECO:0000305}.
FT   CONFLICT    280    280       I -> N (in Ref. 3; AAL87744).
FT                                {ECO:0000305}.
FT   STRAND       43     52       {ECO:0000244|PDB:1UMK}.
FT   STRAND       54     63       {ECO:0000244|PDB:1UMK}.
FT   STRAND       78     85       {ECO:0000244|PDB:1UMK}.
FT   STRAND       88     94       {ECO:0000244|PDB:1UMK}.
FT   STRAND      104    111       {ECO:0000244|PDB:1UMK}.
FT   STRAND      115    118       {ECO:0000244|PDB:1UMK}.
FT   HELIX       126    133       {ECO:0000244|PDB:1UMK}.
FT   STRAND      139    146       {ECO:0000244|PDB:1UMK}.
FT   STRAND      148    153       {ECO:0000244|PDB:1UMK}.
FT   STRAND      156    159       {ECO:0000244|PDB:1UMK}.
FT   STRAND      168    171       {ECO:0000244|PDB:1UMK}.
FT   STRAND      173    180       {ECO:0000244|PDB:1UMK}.
FT   HELIX       181    183       {ECO:0000244|PDB:1UMK}.
FT   HELIX       184    195       {ECO:0000244|PDB:1UMK}.
FT   STRAND      203    212       {ECO:0000244|PDB:1UMK}.
FT   HELIX       213    215       {ECO:0000244|PDB:1UMK}.
FT   HELIX       219    228       {ECO:0000244|PDB:1UMK}.
FT   TURN        230    232       {ECO:0000244|PDB:1UMK}.
FT   STRAND      233    241       {ECO:0000244|PDB:1UMK}.
FT   STRAND      247    252       {ECO:0000244|PDB:1UMK}.
FT   HELIX       255    261       {ECO:0000244|PDB:1UMK}.
FT   HELIX       265    267       {ECO:0000244|PDB:1UMK}.
FT   STRAND      270    275       {ECO:0000244|PDB:1UMK}.
FT   HELIX       277    282       {ECO:0000244|PDB:1UMK}.
FT   HELIX       285    291       {ECO:0000244|PDB:1UMK}.
FT   HELIX       295    297       {ECO:0000244|PDB:1UMK}.
FT   STRAND      298    300       {ECO:0000244|PDB:1UMK}.
SQ   SEQUENCE   301 AA;  34235 MW;  FDCDCDC4EC3570B4 CRC64;
     MGAQLSTLGH MVLFPVWFLY SLLMKLFQRS TPAITLESPD IKYPLRLIDR EIISHDTRRF
     RFALPSPQHI LGLPVGQHIY LSARIDGNLV VRPYTPISSD DDKGFVDLVI KVYFKDTHPK
     FPAGGKMSQY LESMQIGDTI EFRGPSGLLV YQGKGKFAIR PDKKSNPIIR TVKSVGMIAG
     GTGITPMLQV IRAIMKDPDD HTVCHLLFAN QTEKDILLRP ELEELRNKHS ARFKLWYTLD
     RAPEAWDYGQ GFVNEEMIRD HLPPPEEEPL VLMCGPPPMI QYACLPNLDH VGHPTERCFV
     F
//
